跳轉至內容
Merck
  • Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013-01-22)
Michael N Dudley, Paul G Ambrose, Sujata M Bhavnani, William A Craig, Mary Jane Ferraro, Ronald N Jones
摘要

Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum β-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive evaluation, the Clinical and Laboratory Standards Institute recently adopted and published new breakpoints for these agents for use in clinical laboratories and provided updated recommendations for use of the ESBL screening test. This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.

材料
產品編號
品牌
產品描述

USP
氨曲南, United States Pharmacopeia (USP) Reference Standard
Supelco
氨曲南, analytical standard